尤瑞克林联合巴曲酶治疗基底动脉尖综合征临床观察  

Observation of urinary kallidinagenase plus bathoxobin in the treatment of patients with top of the basilar syndrome

作　　者：魏立平[1] 许晓辉[1] 李文波[1] 张耀慧[1] 任向阳[1] 马聪敏[1] 

机构地区：[1]河南洛阳市中心医院神经内科,洛阳471000

出　　处：《中国实用神经疾病杂志》2011年第15期21-23,共3页Chinese Journal of Practical Nervous Diseases

摘　　要：目的探讨尤瑞克林联合巴曲酶治疗基底动脉尖综合症的临床疗效和安全性。方法选择基底动脉尖综合征患者69例,随机分为联合治疗组(尤瑞克林+巴曲酶)25例、巴曲酶组23例和对照组(常规治疗组)21例。观察3组治疗前后美国国立卫生研究院卒中量表(NIHSS)评分的变化。结果 3组治疗前NIHSS评分比较差异无统计学意义(P=0.075),在治疗后14 d2、8 d NIHSS评分显示:联合治疗组神经功能明显改善(14.68±6.19、9.78±6.32),巴曲酶组有所改善(16.45±5.83、14.62±5.75),对照组恢复最差(20.54±5.17、17.26±6.41),3组间比较差异有统计学意义(P=0.004)。所有病例均无严重不良反应发生。结论尤瑞克林联合巴曲酶治疗基底动脉尖综合征安全、有效。Objective To observe the therapeutic effect of urinary kallidinogenase plus batroxobin in treatment of patients with top of the basilar syndrome.Methods Sixty-nine patients with op of the basilar syndrome were assigned into combined treatment group（25 cases）,batroxobin group（23 cases） and control group（21 cases）.All the patients were treated with the conventional neurological treatment.The NIHSS were evaluated before treatment and at 14 days and 28 days after treatment.Results The National Institute of Health Stroke Scale（NIHSS） score was not significant among the three groups before treatment（P=0.075）.After treatment of 14 days and 28 days,the symptom improvement score in urinary kallidinogenase plus batroxobin group was the highest（14.68±6.19,9.78±6.32）,batroxobin group was better（16.45±5.83,14.62±5.75） and control group was the lowest（20.54±5.17,17.26±6.41）.That meant the improvement of neurological deficit in urinary kallidinogenase plus batroxobin was excellent,and there was statistic significance among three groups（P=0.004）.Conclusion The report suggests that urinary kallidinogenase plus batroxobin show effectiveness on the patients with top of the basilar syndrome.

关 键 词：尤瑞克林 巴曲酶 基底动脉尖综合征 

分 类 号：R743.3[医药卫生—神经病学与精神病学]